Novartis Ianalumab Injections For Lupus Nephritis
Posted Date: Aug 2, 2023
- Investigator: Manish Anand
- Specialties: Kidney Disease, Nephrology
- Type of Study: Drug
Brief Summary: This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN as determined by recent biopsy.
Criteria:
Older Than 18, Confirmed Diagnois Of Sle And Renal Biospy Within 6 Months Showing Class Ii, Iv (With Or Without V) Or Class V Alone. Lab Values: Egfr >=25, Upcr >=1.0 G/G From 24 Hour Urine Sample. Exclusions For Severe Renal Impairment, Transplant, Low Hemoglobin, Platelets Or Anc, Intolerance To Mpa Or Corticosteroids
Keywords:
Lupus Nephritis, Proteinuria, Kidney
For More Information:
Manish Anand
5135586742
manish.anand@uc.edu